Loading
Turning Point Therapeutics developed repotrectinib, a pill aimed at lung cancers and other tumours driven by ROS1 or NTRK gene changes. Bristol Myers Squibb bought the company in 2022.
Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX), of San Diego, was a clinical-stage precision oncology company. Its lead asset, repotrectinib, is a tyrosine kinase inhibitor aimed at the ROS1 and NTRK cancer drivers in non-small cell lung cancer and other advanced solid tumours. Bristol Myers Squibb agreed on 3 June 2022 to buy Turning Point for USD 76 per share in cash, an equity value of USD 4.1 billion, and the merger was completed on 17 August 2022.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Bristol Myers Squibb's announcement of 3 June 2022, filed as exhibit 99.1 to Turning Point's 8-K: USD 76.00 per share in cash; Turning Point's investor messages filed the same day give an equity value of USD 4.1 billion | 2022 | $4.1B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2022-06-03 | Turning Point Therapeutics to Bristol Myers Squibb Repotrectinib (Augtyro), ROS1 and NTRK inhibitor | Acquisition | not disclosed | $4.1bn | source |
A ROS1 and NTRK pill that also works after other ROS1 drugs fail, with dizziness as its signature side effect.
Shares Repotrectinib, Bristol Myers Squibb, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Repotrectinib, Bristol Myers Squibb, Small-molecule kinase inhibitors.
Shares Repotrectinib, ROS1, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Repotrectinib, ROS1, NTRK, Small-molecule kinase inhibitors.
Shares Repotrectinib, ROS1, Non-small-cell lung cancer.
Shares Repotrectinib, Bristol Myers Squibb, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/